GENELINK PRESIDENT INTERVIEWED BY IPODESKTOP.COM'S EDITOR, FRANCIS GASKINS
September 10, 2002

A web radio series featuring interviews with CEOs, by IPOdesktop.com

Los Angeles, Calif.--(InternetWire) September 10, 2002-IPOdesktop.com presents GeneLink BioSciences, Inc., (OTCBB:GNLK), an emerging bioscience company that is licensing their proprietary DNA profiling for nutrageneticÍ and dermageneticÍ assessment technology to medical, direct marketing and personal care companies in the nutrition, skin care, wellness and anti-aging industries. The Chairman and CEO of GeneLink, John R. DePhillipo, was interviewed to elaborate on the fascinating opportunities presented by the company's proprietary technology which will provide customized nutrition and skin care to the general public. 

Now, for the first time, vitamins, nutritional supplements, skin and anti-aging creams, along with an assortment of wellness products can be designed to supplement and enhance an individuals' genetic deficiencies. The process begins with GeneLink's patented, self administered DNA Collection Kit® which individuals use to collect their DNA and then mail to GeneLink's lab for processing and analysis. Using GeneLink's proprietary DNA profiling system, the lab can evaluate a persons skin condition, skin aging, nutritional and wellness deficiencies and recommend products designed to enhance or supplement these specific deficiencies. Two licensee companies have begun selling nutritional products using this technology last month. More firms are expected to sign licensing agreements to produce these personal care products using GeneLink's technology in what is eventually to become a dynamic new industry.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.